Journal: Nature Communications
Article Title: CD73 disruption with tumor-specific CRISPR/Cas9 nanoparticles reduces adenosine-mediated immunosuppression and amplifies response to chemotherapy
doi: 10.1038/s41467-026-77547-4
Figure Lengend Snippet: a Size distribution of iRGD-DC@CaP as determined by dynamic light scattering, and morphology of iRGD-DC@CaP as revealed by TEM images. Scale bar: 200 nm. b , c DOX and Cas9 release from iRGD-DC@CaP under different situations ( n = 3 biologically independent samples). Representative flow cytometry analysis images ( d ) and quantitative analysis ( e ) of cellular uptake in B16F10 cells following a 4 h incubation with iRGD-DC@CaP or controls ( n = 3 biologically independent samples). f Confocal laser scanning microscopy images of B16F10 cells following a 4 h incubation with iRGD-DC@CaP or controls. Cas9 was labeled with Alexa Fluor 647 (AF647; red), and the nuclei were stained with DAPI (blue). Scale bars: 50 µm. T7EI assay ( g ) and quantitative analysis ( h ) of indel frequencies of the Nt5e gene in B16F10 cells transfected with iRGD-DC CD73 @CaP or controls for 48 h ( n = 3 biologically independent samples). i Mutation rates of Nt5e examined by NGS analysis in B16F10 cells treated with iRGD-DC CD73 @CaP. j , k Western blot ( j ) and flow cytometry quantitative analysis ( k ) of CD73 protein expression in B16F10 cells after 72 h incubation with iRGD-DC CD73 @CaP or controls ( n = 3 biologically independent samples). l The ADO contents in the cell medium of B16F10 cells after 72 h incubation with iRGD-DC CD73 @CaP or controls detected by ELISA kits ( n = 3 biologically independent samples). The experiments for f and i were independently repeated three times with similar results. Data is presented as the mean ± SD. Statistical difference was assessed in ( e , h , j , k and l ) using one-way ANOVA with Dunnett’s multiple comparison test by comparing the iRGD-DC CD73 @CaP group with each of the other treatment groups. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. G1: saline (negative control); G2: Free Cas9 RNP; G3: iRGD-modified nanoparticles loaded with scrambled sgRNA (iRGD-DC Scr @CaP, negative control); G4: Lipofectamine™ CRISPRMAX™-mediated delivery of Cas9/sgCD73 (MAX Cas9/sgCD73, positive control); G5: nanoparticle without iRGD loaded with Cas9/sgCD73 (DC CD73 @CaP); G6: iRGD-modified nanoparticle loaded with Cas9/sgCD73 (iRGD-DC CD73 @CaP). The exact P value and Source data are provided as a Source Data file.
Article Snippet: The blocked PVDF membrane using skim milk was incubated with primary antibody against CD73 (12231-1-AP, Proteintech) at a dilution of 1:2000 overnight at 4 °C.
Techniques: Dynamic Light Scattering Assay, Morphology, Flow Cytometry, Analysis, Incubation, Confocal, Laser-Scanning Microscopy, Labeling, Staining, T7EI Assay, Transfection, Mutagenesis, Western Blot, Expressing, Enzyme-linked Immunosorbent Assay, Comparison, Saline, Negative Control, Modification, Positive Control